Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study
- PMID: 20310015
- DOI: 10.1002/ibd.21260
Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study
Abstract
Background: During active ulcerative colitis (UC), vast numbers of granulocytes, monocytes/macrophages (GM) infiltrate the mucosal tissue and can potentially exacerbate inflammation and injury. Accordingly, we were interested to see if selective depletion of GM by adsorption (GMA) impacts mucosal healing (MH) in UC patients.
Methods: In all, 124 patients with clinically and endoscopically active UC received 5 or 10 GMA sessions at one or two sessions/week. The endoscopic severity of mucosal inflammation at entry and 1 week after the last GMA session were scored as follows: 0 = normal mucosa and inactive disease; 1 = mild inflammation; 2 = moderate inflammation; 3 = severe inflammation. Likewise, a score 0 or 1 at post-GMA course was defined as MH.
Results: At entry the endoscopic severity of the mucosal inflammation was 2 in 100 patients (81%) and 3 in 24 patients (19%). Following the course of GMA, 56 patients (45%) achieved clinical remission (normal stool frequency and no rectal bleeding). Thirty-four of these 56 responders achieved MH; 32 (94%) of the 34 patients with MH had an endoscopic score of 2 (moderate inflammation) at entry. The maintained clinical remission rate was significantly higher in the 34 patients who achieved MH as compared with 22 patients who achieved clinical remission without MH (P = 0.0005).
Conclusions: MH is achieved more frequently in patients with moderate than with severe endoscopic severity at entry. Further, patients with MH have a reduced risk of future clinical relapse as compared with patients who achieve remission without MH.
Similar articles
-
In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients.Dig Liver Dis. 2008 Sep;40(9):731-6. doi: 10.1016/j.dld.2008.02.012. Epub 2008 Apr 2. Dig Liver Dis. 2008. PMID: 18387860
-
Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.BMC Gastroenterol. 2018 Aug 1;18(1):120. doi: 10.1186/s12876-018-0853-4. BMC Gastroenterol. 2018. PMID: 30068300 Free PMC article.
-
Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings.Inflamm Bowel Dis. 2006 Aug;12(8):719-26. doi: 10.1097/00054725-200608000-00008. Inflamm Bowel Dis. 2006. PMID: 16917227
-
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.World J Gastroenterol. 2006 Dec 21;12(47):7568-77. doi: 10.3748/wjg.v12.i47.7568. World J Gastroenterol. 2006. PMID: 17171783 Free PMC article. Review.
-
Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders.Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):327-33. doi: 10.1586/17474124.2014.953060. Epub 2014 Aug 27. Expert Rev Gastroenterol Hepatol. 2015. PMID: 25160857 Review.
Cited by
-
Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis.World J Gastroenterol. 2021 Mar 28;27(12):1194-1212. doi: 10.3748/wjg.v27.i12.1194. World J Gastroenterol. 2021. PMID: 33828394 Free PMC article.
-
The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.Clin Exp Immunol. 2011 Jan;163(1):50-8. doi: 10.1111/j.1365-2249.2010.04279.x. Epub 2010 Nov 16. Clin Exp Immunol. 2011. PMID: 21078086 Free PMC article. Review.
-
Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study.J Gastroenterol. 2011 Aug;46(8):1003-9. doi: 10.1007/s00535-011-0428-4. Epub 2011 Jun 17. J Gastroenterol. 2011. PMID: 21681409 Clinical Trial.
-
Chronic Antibiotic-Refractory Pouchitis: Management Challenges.Clin Exp Gastroenterol. 2021 Jun 14;14:277-290. doi: 10.2147/CEG.S219556. eCollection 2021. Clin Exp Gastroenterol. 2021. PMID: 34163205 Free PMC article. Review.
-
"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.World J Gastrointest Pathophysiol. 2014 May 15;5(2):54-62. doi: 10.4291/wjgp.v5.i2.54. World J Gastrointest Pathophysiol. 2014. PMID: 24891976 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical